Geron Corporation (NASDAQ:GERN – Get Free Report)’s share price was up 4.5% on Tuesday. The company traded as high as $0.9849 and last traded at $0.9840. 1,996,618 shares were traded during trading, a decline of 86% from the average session volume of 14,024,357 shares. The stock had previously closed at $0.9419.
Analysts Set New Price Targets
GERN has been the topic of a number of recent analyst reports. Needham & Company LLC lowered their price objective on Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Wedbush decreased their target price on shares of Geron to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 28th. Finally, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.75.
Check Out Our Latest Stock Report on Geron
Geron Trading Up 6.7%
The company has a market capitalization of $647.46 million, a P/E ratio of -12.56 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a current ratio of 6.31 and a quick ratio of 4.61. The stock’s 50 day moving average is $1.17 and its 200-day moving average is $1.40.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC bought a new position in Geron in the 2nd quarter worth about $15,648,000. Bank of America Corp DE bought a new stake in Geron in the 2nd quarter worth approximately $4,524,000. Edmond DE Rothschild Holding S.A. purchased a new stake in Geron during the 2nd quarter valued at $2,982,000. Janus Henderson Group PLC raised its stake in Geron by 826.7% during the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock valued at $3,304,000 after buying an additional 1,978,839 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Geron by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,799,521 shares of the biopharmaceutical company’s stock valued at $2,681,000 after buying an additional 1,062,355 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.
Geron Company Profile
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Featured Stories
- Five stocks we like better than Geron
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
